News for ACADIA Pharma Stock (ACAD)

HAGENS BERMAN Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact its Attorneys Before June 18th Application Deadline in Securities Fraud Lawsuit

Newsfile Corp • 06/03/21

INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Newsfile Corp • 06/03/21

NUPLAZID® (pimavanserin) Efficacy Data from Open-Label Extension (OLE) Study Published in Parkinsonism and Related Disorders

Business Wire • 06/03/21

INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Newsfile Corp • 06/02/21

Should You Buy ACADIA Pharmaceuticals Stock At $22?

Forbes • 06/02/21

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Newsfile Corp • 06/01/21

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Acadia Pharmaceuticals Inc. Investors With Losses Over $100K to Secure Counsel Before Important June 18 Deadline in Securities Class Action - ACAD

PRNewsWire • 05/28/21

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Acadia Pharmaceuticals Inc. (ACAD) Investors

PRNewsWire • 05/28/21

SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Newsfile Corp • 05/27/21

HAGENS BERMAN Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm, Securities Class Action Pending, June Deadline Approaching

Newsfile Corp • 05/24/21

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Acadia Pharmaceuticals Inc. (ACAD)

PRNewsWire • 05/24/21

HAGENS BERMAN Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm, Securities Fraud Class Action Filed

Newsfile Corp • 05/20/21

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm to Recover Losses Due to Alleged Securities Fraud

Newsfile Corp • 05/17/21

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Acadia Pharmaceuticals Inc. (ACAD)

PRNewsWire • 05/13/21

ACAD INVESTORS WHO LOST MONEY: HAGENS BERMAN, National Trial Attorneys, Alerts Acadia Pharmaceuticals (ACAD) Investors to Securities Class Action, Advises Investors with Losses to Contact Its Attorneys Now

Newsfile Corp • 05/10/21

ACADIA (ACAD) Q1 Earnings Beat, Revenues Fall Shy of Estimates

Zacks Investment Research • 05/06/21

ACADIA Pharmaceuticals, Inc. (ACAD) CEO Stephen Davis on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha • 05/06/21

ACAD DEADLINE: HAGENS BERMAN, National Trial Attorneys, Alerts Acadia Pharmaceuticals (ACAD) Investors to Securities Class Action, Advises Investors with Losses to Contact Its Attorneys Now

Newsfile Corp • 05/05/21

Acadia Pharmaceuticals Reports First Quarter 2021 Financial Results

Business Wire • 05/05/21

ACAD INVESTOR DEADLINE: HAGENS BERMAN, National Trial Attorneys, Advises Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Filed

Newsfile Corp • 04/29/21

ACAD Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds ACADIA Pharmaceuticals Inc. Shareholders of Class Action and Encourages Shareholders to Contact the Firm

Business Wire • 04/29/21

EQUITY ALERT: ROSEN, A LEADING LAW FIRM, Encourages Acadia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Deadline – ACAD

Business Wire • 04/27/21

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Acadia Pharmaceuticals Inc. (ACAD) Investors

Business Wire • 04/26/21

Shareholder Alert: Robbins LLP Is Investigating Acadia Pharmaceuticals Inc. (ACAD) on Behalf of Shareholders

Business Wire • 04/23/21

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Pending, Deadline Approaching

Newsfile Corp • 04/23/21